With over 9 million daily interactions across nearly 8,000 stores, Walgreens' vast physical footprint is the primary engine generating the real-world data that powers its analytics for pharma partners. Its brick-and-mortar scale is its core data advantage.

Instead of waiting for customers to churn, use AI to monitor key engagement metrics in real time (e.g., portal logins, link clicks). When a user shows signs of disengagement, trigger a personalized, automated nudge via SMS or email to get them back on track before they are lost.

The effectiveness of AI and machine learning models for predicting patient behavior hinges entirely on the quality of the underlying real-world data. Walgreens emphasizes its investment in data synthesis and validation as the non-negotiable prerequisite for generating actionable insights.

AI can analyze a customer's support history to predict their behavior. For instance, if a customer consistently calls about shipping delays, an AI agent can proactively contact them with an update before they reach out, transforming a reactive, negative interaction into a positive customer experience.

Historically, channel agents focused on front-end sales and were often blind to back-end customer churn. Sophisticated partners now use data analytics and AI to identify churn risks, pinpoint cross-sell opportunities, and actively manage their existing revenue base.

The friction of navigating insurance and pharmacies is so high that chronic disease patients often give up, skipping tests or medications and directly worsening their health. AI can automate these tedious tasks, removing the barriers that lead to non-compliance and poor health outcomes.

Chronic disease patients face a cascade of interconnected problems: pre-authorizations, pharmacy stockouts, and incomprehensible insurance rules. AI's potential lies in acting as an intelligent agent to navigate this complex, fragmented system on behalf of the patient, reducing waste and improving outcomes.

Walgreens prioritizes tackling barriers to medication access—such as cost and prior authorizations—believing that adherence can only be addressed once a patient can consistently obtain their therapy. This frames the two issues as a sequence, not parallel challenges.

Unlike the top-down, regulated rollout of EHRs, the rapid uptake of AI in healthcare is an organic, bottom-up movement. It's driven by frontline workers like pharmacists who face critical staffing shortages and need tools to manage overwhelming workloads, pulling technology in out of necessity.